For example, a high CD4 + /CD8 + cell count ratio of infiltrating lymphocytes in the tumor was associated with a poor prognosis [1], and GBM with a high mutational burden responded significantly to the administration of ICI nivolumab [2]. This evidence concerns the gene CD4 and glioblastoma.